Search over 3,000 reports

    Parkinson's Disease - Market Insights, Epidemiology and Market Forecast - 2025

    Parkinson's Disease - Market Insights, Epidemiology and Market Forecast - 2025
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 69
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIMI0022
    DelveInsight's "Parkinson's Disease - Market Insights, Epidemiology and Market Forecast - 2025"report provides an overview of Parkinson's disease (PD), epidemiology and market trend of the Parkinson's disease (PD) for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

    The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Parkinson's disease (PD) from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Parkinson's disease (PD) till 2025.The Report also covers market drivers, market barriers and unmet medical need.

    Our report provides the diagnosed cases of Parkinson's disease (PD). Changes in diagnostic practice over time and increase in aging population will slowly increase the diagnosed cases of PD. According to DelveInsight, the prevalent population of Parkinson's disease (PD) is expected to reach up to XXX cases by the end of 2025 at a CAGR of 4.69% from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.

    The market size is driven by several approved drugs that are being used for the treatment of Parkinson's disease such as Neupro (UCB Group of Companies), Xadago (Newron Pharmaceuticals S.p.A.) and Exelon (Novartis).

    United States contributes the major share of Parkinson's disease (PD) market as compared to EU5 countries and Japan. The therapeutic market of PD in 7MM is expected to reach USD 4.91 Billion in 2025 at the CAGR of XX% from 2015-2025.

    Key Coverage and Benefits:

    • The report will help in developing business strategies by understanding the trends shaping and driving the global Parkinson's disease (PD) market.
    • Organize sales and marketing efforts by identifying the best opportunities for Parkinson's disease in US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
    • To understand the future market competition in the Parkinson's disease market and Insightful review of the key market drivers and barriers.
    • To understand the regulatory scenario in major markets.
    • The report provides historical as well as forecasted epidemiology of Parkinson's disease in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
    • The Report also covers the detailed historical and forecasted Parkinson's disease market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.

    1. Report Introduction
    2. Parkinson Disease Market Overview at a Glance
    3. Total Market Share Distribution of Parkinson Disease for 7 MM in 2016
    4. Total Market Share Distribution of Parkinson Disease for 7 MM in 2025
    5. Parkinson Disease
    6. Overview
    6.1. Symptoms
    6.2. Pathophysiology
    6.3. Staging
    6.4. Diagnosis
    7. Parkinson's disease (PD) Geography wise Diagnosed Cases
    8. 7MM Diagnosed PD Cases in 2016
    9. 7MM Diagnosed PD Cases in 2025
    10. Epidemiology and Patient Population
    11. Key Points
    12. Epidemiology Forecast Overview
    12.1. United States
    12.2. Diagnosed Cases of Parkinson Disease in United States
    12.3. Europe
    12.4. Germany
    12.5. Diagnosed Cases of Parkinson Disease in Germany
    12.6. France
    12.7. Diagnosed Cases of Parkinson Disease in France
    12.8. United Kingdom
    12.9. Diagnosed Cases of Parkinson Disease in United Kingdom
    12.10. Spain
    12.11. Diagnosed Cases of Parkinson Disease in Spain
    12.12. Italy
    12.13. Diagnosed Cases of Parkinson Disease in Italy
    12.14. Japan
    13. Diagnosed Cases of Parkinson Disease in Japan
    14. Treatment Algorithm
    15. Unmet Needs
    16. Marketed Drugs
    16.1.1. Top Marketed Drugs for Parkinson disease
    16.1.2. Azilect: Teva Pharmaceutical Industries
    16.1.3. Drug Description
    16.1.4. Mechanism of Action
    16.1.5. Regulatory Milestones
    16.1.6. Advantages & Disadvantages
    16.1.7. Safety and Efficacy of Azilect
    16.1.8. Product Profile
    16.1.9. Exelon/Exelon Patch: Novartis
    16.1.10. Drug Description
    16.1.11. Mechanism of Action
    16.1.12. Regulatory Milestones
    16.1.13. Advantages & Disadvantages
    16.1.14. Safety and Efficacy of Exelon
    16.1.15. Product Profile
    16.1.16. Stalevo: Orion Corporation
    16.1.17. Drug Description
    16.1.18. Mechanism of Action
    16.1.19. Regulatory Milestones
    16.1.20. Advantages & Disadvantages
    16.1.21. Safety and Efficacy of Stalevo
    16.1.22. Product Profile
    16.1.23. Comtan/Comtess: Orion Corporation
    16.1.24. Drug Description
    16.1.25. Mechanism of Action
    16.1.26. Regulatory Milestones
    16.1.27. Advantages & Disadvantages
    16.1.28. Safety and Efficacy of Comtan/Comtess
    16.1.29. Product Profile
    17. Emerging Therapies
    18. Major Pipeline drugs
    18.1. Tozadenant
    18.2. Advantages & Disadvantages
    18.3. Product Profile
    18.4. Clinical Development
    18.5. Clinical Pipeline Activity
    18.6. Ongoing Trials Information
    18.7. Clinical Trial by Phase
    18.8. CVT-301
    18.9. Product Profile
    18.10. Clinical Development
    18.11. Clinical Pipeline Activity
    18.12. Ongoing Trials Information
    18.13. Clinical Trial by Phase
    18.14. Gene Therapy: Future possible treatment option for Parkinson's Disease
    19. Parkinson Disease: Country-Wise Market Analysis
    20. Total Market Size of Parkinson Disease for 7 MM (2015-2025)
    21. Overview on Total Parkinson Disease Market Geography wise (2016 & 2025)
    22. Overview on Total Parkinson Disease Market (2016 & 2025)
    22.1. United States Market Size
    22.2. Europe Market Size
    22.2.1. Germany Market Size
    22.2.2. France Market Size
    22.2.3. United Kingdom Market Size
    22.2.4. Spain Market Size
    22.2.5. Italy Market Size
    22.3. Japan Market Size
    23. Market Drivers
    24. Market Restraints
    25. Appendix
    26. Report Methodology
    27. Consulting Services
    28. Disclaimer
    29. About DelveInsight
    Table1: Diagnosed Cases of Parkinson Disease in United States (2015-2025)
    Table 2: Diagnosed Cases of Parkinson Disease in Germany (2015-2025)
    Table 3: Diagnosed Cases of Parkinson Disease in France (2015-2025)
    Table 4: Diagnosed Cases of Parkinson Disease in United Kingdom (2015-2025)
    Table 5: Diagnosed Cases of Parkinson Disease in Spain (2015-2025)
    Table 6: Diagnosed Cases of Parkinson Disease in Italy (2015-2025)
    Table 7: Diagnosed Cases of Parkinson Disease in Japan (2015-2025)
    Table 8: Classes of Drugs used for management of Parkinson's Disease
    Table 9: List of Marketed Drugs for Parkinson Disease
    Table 10: List of Pipeline Phase III Drugs for Parkinson Disease
    Table 11: List of Pipeline Phase II Drugs for Parkinson Disease
    Table 12: Tozadenant, Clinical Trials by Zone, 2017
    Table 13: Clinical Trials by Trial status, 2017
    Table 14: CVT-301, Clinical Trials by Zone, 2017
    Table 15: Clinical Trials by Trial status, 2017
    Table 16: Total 7 Major Market Size of Parkinson's disease in USD Million (2015-2025)
    Table 17: United States Market Size of Parkinson Disease in USD Million, (2015-2025)
    Table 18: Germany Market Size of Parkinson Disease in USD Million, (2015-2025)
    Table 19: France Market Size of Parkinson Disease in USD Million, (2015-2025)
    Table 20: United Kingdom Market Size of Parkinson Disease in USD Million, (2015-2025)
    Table 21: Spain Market Size of Parkinson Disease in USD Million, (2015-2025)
    Table 22: Italy Market Size of Parkinson Disease in USD Million, (2015-2025)
    Table 23: Japan Market Size of Parkinson Disease in USD Million, (2015-2025)
    Figure 1: Types of Parkinson Disease
    Figure 2: Pathophysiology of Parkinson's Disease
    Figure 3: Diagnosed Cases of Parkinson Disease in United States (2015-2025)
    Figure 4: Diagnosed Cases of Parkinson Disease in Germany (2015-2025)
    Figure 5: Diagnosed Cases of Parkinson Disease in France (2015-2025)
    Figure 6: Diagnosed Cases of Parkinson Disease in United Kingdom (2015-2025)
    Figure 7: Diagnosed Cases of Parkinson Disease in Spain (2015-2025)
    Figure 8: Diagnosed Cases of Parkinson Disease in Italy (2015-2025)
    Figure 9: Diagnosed Cases of Parkinson Disease in Japan (2015-2025)
    Figure 10: Treatment Algorithm of Parkinson's Disease
    Figure 11: Treatment Algorithm of Parkinson's Disease- continued
    Figure 12: Tozadenant, Clinical Trials by Zone (%), 2017
    Figure 13: Tozadenant, Clinical Trials by Trial status (%), 2017
    Figure 14: CVT-301, Clinical Trials by Zone (%), 2017
    Figure 15: CVT-301, Clinical Trials by Trial status (%), 2017
    Figure 16: Total 7 Major Market Size of Parkinson's disease in USD Millions (2015-2025)
    Figure 17: Total Market Size of Parkinson Disease-Geography wise in USD Million, (2016)
    Figure 18: Total Market Size of Parkinson Disease-Geography wise in USD Million, (2025)
    Figure 19: Total Market Size of Parkinson Disease in USD Million, (2016)
    Figure 20: Total Market Size of Parkinson Disease in USD Million, (2025)
    Figure 21: United States Market Size of Parkinson Disease in USD Million, (2015-2025)
    Figure 22: Germany Market Size of Parkinson Disease in USD Million, (2015-2025)
    Figure 23: France Market Size of Parkinson Disease in USD Million, (2015-2025)
    Figure 24: United Kingdom Market Size of Parkinson Disease in USD Million, (2015-2025)
    Figure 25: Spain Market Size of Parkinson Disease in USD Million, (2015-2025)
    Figure 26: Italy Market Size of Parkinson Disease in USD Million, (2015-2025)
    Figure 27: Japan Market Size of Parkinson Disease in USD Million, (2015-2025)
    Parkinson's Disease Market (7MM)

    Parkinson's Disease Market forecasting

    Parkinson's Disease Sales forecasting

    Parkinson's Disease Market segments

    Parkinson's Disease Epidemiology

    Parkinson's Disease Pipeline products and technologies

    Parkinson's Disease Competitive landscape

    Parkinson's Disease SWOT analysis

    Parkinson's Disease Market Driver's and barriers

    Parkinson's Disease Key Companies and Funding



    • Single User License
      (20% Off)
      $5,750.00
      $4600
    • Site License
      (30% Off)
      $11,500.00
      $8050
    • Global License
      (40% Off)
      $17,250.00
      $10350

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap